InvestorsHub Logo
Followers 33
Posts 5301
Boards Moderated 0
Alias Born 01/23/2019

Re: None

Wednesday, 11/24/2021 10:26:53 AM

Wednesday, November 24, 2021 10:26:53 AM

Post# of 426859
Pfizer needs Vascepa!!!!

BRIEF-Pfizer Announces Topline Results From Phase 2B Trial Of Vupanorsen In Statin-Treated Participants With Dyslipidemia
REUTERS 10:23 AM ET 11/24/2021
Symbol Last Price Change
PFE 51.025down -0.055 (-0.1077%)
QUOTES AS OF 10:23:48 AM ET 11/24/2021
Nov 24 (Reuters) - Pfizer Inc(PFE):

* PFIZER ANNOUNCES TOPLINE RESULTS FROM PHASE 2B TRIAL OF VUPANORSEN IN STATIN-TREATED PARTICIPANTS WITH DYSLIPIDEMIA

* PFIZER INC(PFE) - PHASE 2B TRIAL OF VUPANORSEN MET ITS PRIMARY ENDPOINT

* PFIZER - PHASE 2B TRIAL ACHIEVED STATISTICALLY SIGNIFICANT REDUCTION IN NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL AT ALL DOSE LEVELS, VERSUS PLACEBO

* PFIZER - PHASE 2B TRIAL ACHIEVED STATISTICALLY SIGNIFICANT REDUCTION IN SECONDARY ENDPOINT OF TRIGLYCERIDES AT ALL DOSE LEVELS, COMPARED TO PLACEBO

* PFIZER INC(PFE) - WILL CONTINUE TO REVIEW FINDINGS TO DETERMINE NEXT STEPS REGARDING FUTURE DEVELOPMENT OF VUPANORSEN Further company coverage:

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News